1. Scrip
  2. >>Business

ADC Therapeutics To Wind Up Zynlonta Study In Frail Patients After Deaths

Study To End Despite No Clear Link With Treatment

 
• By Andrew McConaghie

The company had hoped its antibody drug conjugate could help frail and elderly B-cell lymphoma patients ineligible for chemotherapy, but the trial will now close following patient deaths.

Frail Patient
The study aimed to help elderly patients who were frail and unfit for standard first line chemotherapy treatment.

ADC Therapeutics is to end a Phase II study of its antibody-drug conjugate Zynlonta in unfit or frail patients with previously untreated diffuse large B-cell lymphoma, after concluding the risks of the trial outweighed benefits.

That came after 12 patients out of 40 enrolled on the LOTIS-09 study died, including seven respiratory event-related deaths. The trial combined Zynlonta (loncastuximab tesirine-lpyl) with rituximab, and while no clear link between the treatment and deaths was established, ADC Therapeutics will now wind up the study

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.